Clinical Trials Sponsored by Janssen Pharmaceuticals

Total 22175 results

Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.

Bipolar Disorder | Manic Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Italy, Russian Federation, Brazil, Portugal, Belgium, Spain, United States, Austria, Hungary, Turkey, Germany, Australia, Poland, Mexico, Finland, Slovakia, Lebanon, Czechia, Denmark, Jordan, Sweden
Janssen Pharmaceutica N.V., Belgium

Active, not recruiting

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

Bipolar Disorder

United States, Spain, Poland, Canada
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Ponesimod in Healthy Adult Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study of JNJ-64140284 in Healthy Male Participants (AMPAR)

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

Prostate Cancer

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Slovenia, Turkey, Sweden, Austria, Russian Federation, Luxembourg, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Prostate Cancer

United Kingdom, Belgium, Hungary, Germany
Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Idylla IFV-RSV Panel Clinical Testing (RP1)

Respiratory Tract Infections | Influenza, Human | Respiratory Syncytial Virus Infections

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Multiple Myeloma

France, Poland, Ukraine, Germany, Spain, Israel, Portugal, Slovenia, South Africa, Turkey, Greece, Estonia, Russian Federation, Hungary, Austria, Lithuania, Macedonia, The Former Yugoslav Republic of, Latvia, Croatia, Denmark, A...
Janssen Pharmaceutica N.V., Belgium

Completed

Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate

Schizophrenia

Turkey, Russian Federation, Croatia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients

Major Depressive Disorder

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Retrospective Survey of Re-treatment With Bortezomib

Multiple Myeloma | Hematological Cancer

Greece
Janssen Pharmaceutica N.V., Belgium

Completed

Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients

Psychotic Disorders | Schizophrenia | Emergency Treatment
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)

Gastroesophageal Reflux | Heartburn
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

HIV Infections

Germany, Spain, United States, Canada, Taiwan, France, Italy, Argentina, United Kingdom, Russian Federation, Australia
University of Washington
Janssen Pharmaceuticals

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma

United States
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Active, not recruiting

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Healthy

United States
University Hospital, Lille
Janssen Pharmaceuticals

Terminated

Changes in Body Composition Under Ustekinumab in PsA (STELARA-CC)

Psoriatic Arthritis

France
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

Relapsed/Refractory Multiple Myeloma

Germany, Italy, Belgium, Spain, Netherlands, France, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Active, not recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

United Kingdom, Korea, Republic of, France, Belgium, Japan, Taiwan, Austria, Canada, Netherlands, Spain, Italy, Germany, Australia, Switzerland, Mexico, Sweden, Greece, Argentina, Colombia, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Critical Confirmed Coronavirus Disease (COVID)-19

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants (AQUARiUS)

Prostatic Neoplasms

France, United Kingdom, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

Tracking Biologics Along the Silk Road (HARIR)

Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative

Saudi Arabia, Egypt, Qatar, Algeria, Kuwait
Janssen Pharmaceutica N.V., Belgium

Completed

Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO)

Psoriasis

France, United Kingdom, Spain, Belgium, Israel, Netherlands, Greece, South Africa, Russian Federation, Ireland, Austria, Norway
Vanderbilt University
Janssen Pharmaceutica

Completed

Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

Unipolar Depression

United States
Janssen Pharmaceutica N.V., Belgium

Completed

The Prolonged Use of Topiramate for Preventing Migraine Headaches (PROMPT)

Migraine

France, Poland, United Kingdom, Belgium, Germany, Spain, Portugal, Slovenia, Bulgaria, Saudi Arabia, Switzerland, Denmark, Greece, Russian Federation, Turkey, Hungary, Austria, Ireland, Norway, Czech Republic
Janssen Pharmaceutica N.V., Belgium

Terminated

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

Schizophrenia | Cognition Disorders | Alzheimer's Disease

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine

Migraine
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis

Arthritis | Osteoarthritis | Rheumatoid Arthritis
Janssen Pharmaceutica N.V., Belgium

Completed

Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.

Female Contraception | Contraception
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Healthy

United States
Boston Medical Center
Janssen Pharmaceuticals

Completed

Daratumumab for the Treatment of Patients With AL Amyloidosis

AL Amyloidosis

United States
University of Pittsburgh
Janssen Pharmaceuticals

Completed

Risperdal Consta for Bipolar Disorder

Bipolar I Disorder

United States

Clinical Trials Sponsored by Janssen Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations